Extracellular fibrinogen binding protein, Efb, from Staphylococcus aureus binds to platelets and inhibits platelet aggregation

Summary

S. aureus produces and secretes a protein, extracellular fibrinogen binding protein (Efb), which contributes to virulence in wound infection. We have shown here that Efb is a potent inhibitor of platelet aggregation. Efb can bind specifically to platelets by two mechanisms; 1) to fibrinogen naturally bound to the surface of activated platelets and 2) also directly to a surface localized component on the platelets. This latter binding of Efb is independent of fibrinogen. The specific binding of Efb to the putative receptor on the platelet surface results in a stimulated, non-functional binding of fibrinogen in a dose dependent manner, distinct from natural binding of fibrinogen to platelets. The natural binding of fibrinogen to GPIIb/IIIa on activated platelets could be blocked by a monoclonal antibody against this integrin, whereas the Efb-mediated fibrinogen binding could not be blocked. The enhanced Efb-dependent fibrinogen binding to platelets is of a nature that does not promote aggregation of the platelets; instead it inhibits aggregation. The anti-thrombotic action of Efb may explain the effect of Efb on wound healing, which is delayed in the presence of Efb.

Keywords

Bacteria - coagulation inhibitors - fibrinogen / fibrin - platelet physiology

• References

• 1 Foster TJ, Hook M. Surface protein adhesins of Staphylococcus aureus. Trends Microbiol 1998; 06 (12) 484-8.
• 2 Flock JI. Extracellular-matrix-binding proteins as targets for the prevention of Staphylococcus aureus infections. Mol Med Today 1999; 05 (12) 532-7.
• 3 Yeaman MR, Sullam PM, Dazin PF. et al. Characterization of Staphylococcus aureusplatelet binding by quantitative flow cytometric analysis. J Infect Dis 1992; 166 (01) 65-73.
• 4 Nicolau DP, Freeman CD, Nightingale CH. et al. Reduction of bacterial titers by low-dose aspirin in experimental aortic valve endocarditis. Infect Immun 1993; 61 (04) 1593-5.
• 5 Sullam PM, Bayer AS, Foss WM. et al. Diminished platelet binding in vitro by Staphylococcus aureus is associated with reduced virulence in a rabbit model of infective endocarditis. Infect Immun 1996; 64 (12) 4915-21.
• 6 Siboo IR, Cheung AL, Bayer AS. et al. Clumping factor A mediates binding of Staphylococcus aureus to human platelets. Infect Immun 2001; 69 (05) 3120-7.
• 7 Brien O.L, Kerrigan SW, Kaw G. et al. Multiple mechanisms for the activation of human platelet aggregation by Staphylococcus aureus: roles for the clumping factors ClfA and ClfB, the serine-aspartate repeat protein SdrE and protein A. Mol Microbiol 2002; 44 (04) 1033-44.
• 8 Nguyen T, Ghebrehiwet B, Peerschke EI. Staphylococcus aureus protein A recognizes platelet gC1qR/p33: a novel mechanism for staphylococcal interactions with platelets. Infect Immun 2000; 68 (04) 2061-8.
• 9 Hutton RA, Latten MA, Tuddenham EGD. Normal Haemostasis. In: Hoffbrand AV, Mitchell SLewis, Tuddenham EGD. editors. Postgraduate Haematology. 4th ed. ed: Heinemann Medical Books; 1999
• 10 Pierce GF, Mustoe TA, Altrock BW. et al. Role of platelet-derived growth factor in wound healing. J Cell Biochem 1991; 45 (04) 319-26.
• 11 Steed DL, Goslen JB, Holloway GA. et al. Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. CT-102 activated platelet supernatant, topical versus placebo. Diabetes Care 1992; 15 (11) 1598-604.
• 12 Palma M, Nozohoor S, Schennings T. et al. Lack of the extracellular 19-kilodalton fibrinogen-binding protein from Staphylococcus aureus decreases virulence in experimental wound infection. Infect Immun 1996; 64 (12) 5284-9.
• 13 Mamo W, Boden M, Flock JI. Vaccination with Staphylococcus aureus fibrinogen binding proteins (FgBPs) reduces colonisation of S. aureus in a mouse mastitis model. FEMS Immunol Med Microbiol 1994; 10 (01) 47-53.
• 14 Colque-Navarro P, Palma M, Soderquist B. et al. Antibody responses in patients with staphylococcal septicemia against two Staphylococcus aureus fibrinogen binding proteins: clumping factor and an extracellular fibrinogen binding protein. Clin Diagn Lab Immunol 2000; 07 (01) 14-20.
• 15 Palma M, Wade D, Flock M. et al. Multiple binding sites in the interaction between an extracellular fibrinogen-binding protein from Staphylococcus aureus and fibrinogen. J Biol Chem 1998; 273 (21) 13177-81.
• 16 Boden MK, Flock JI. Cloning and characterization of a gene for a 19 kDa fibrinogen-binding protein from Staphylococcus aureus. Mol Microbiol 1994; 12 (04) 599-606.
• 17 Palma M, Shannon O, Quezada HC. et al. Extracellular fibrinogen-binding protein, Efb, from Staphylococcus aureus blocks platelet aggregation due to its binding to the alphachain. J Biol Chem 2001; 276 (34) 31691-7.
• 18 Le Blanc K, Berg A, Palmblad J. et al. Defective platelet aggregation in polycythaemia vera is not caused by impaired calcium signaling, phospholipase D activation or decreased amounts of focal adhesion proteins. Eur J Haematol 2000; 65 (05) 322-30.
• 19 Coller BS, Anderson K, Weisman HF. New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb Haemost 1995; 74 (01) 302-8.
• 20 Ruf A, Patscheke H. Flow cytometric detection of activated platelets: comparison of determining shape change, fibrinogen binding, and P-Selectin expression. Seminars in Thrombosis and Haemostasis 1995; 21 (02) 146-51.
• 21 Shattil SJ, Hoxie JA, Cunningham M. et al. Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. J Biol Chem 1985; 260 (20) 11107-14.
• 22 Michelson AD, Barnard MR, Krueger LA. et al. Evaluation of platelet function by flow cytometry. Methods 2000; 21 (03) 259-70.
• 23 Litjens PE, Akkerman JW, van Willigen G. Platelet integrin alphaIIbbeta3: target and generator of signalling. Platelets 2000; 11 (06) 310-9.
• 24 Savage B, Cattaneo M, Ruggeri ZM. Mechanisms of platelet aggregation. Curr Opin Hematol 2001; 08 (05) 270-6.
• 25 Harrison P, Wilbourn B, Debili N. et al. Uptake of plasma fibrinogen into the alpha granules of human megakaryocytes and platelets. J Clin Invest 1989; 84 (04) 1320-4.
• 26 Handagama P, Scarborough RM, Shuman MA. et al. Endocytosis of fibrinogen into megakaryocyte and platelet alpha- granules is mediated by alpha IIb beta 3 (glycoprotein IIb-IIIa). Blood 1993; 82 (01) 135-8.
• 27 Heilmann C, Herrmann M, Kehrel BE. et al. Platelet-Binding Domains in 2 Fibrinogen-Binding Proteins of Staphylococcus aureus Identified by Phage Display. J Infect Dis 2002; 186 (01) 32-9.
• 28 Herrmann M, Lai QJ, Albrecht RM. et al. Adhesion of Staphylococcus aureus to surface-bound platelets: role of fibrinogen/fibrin and platelet integrins. J Infect Dis 1993; 167 (02) 312-22.
• 29 Bayer AS, Sullam PM, Ramos M. et al. Staphylococcus aureus induces platelet aggregation via a fibrinogen-dependent mechanism which is independent of principal platelet glycoprotein IIb/IIIa fibrinogen-binding domains. Infect Immun 1995; 63 (09) 3634-41.
• 30 Bennett JS. Platelet-fibrinogen interactions. Annals New York Academy of Sciences 2001; 936: 340-54.
• 31 Bonnefoy A, Hantgan R, Legrand C. et al. A model of platelet aggregation involving multiple interactions of thrombospondin-1, fibrinogen, and GPIIbIIIa receptor. J Biol Chem 2001; 276 (08) 5605-12.
• 32 Yeaman MR, Bayer AS. Staphylococcus aureus, Platelets, and the Heart. Curr Infect Dis Rep 2000; 02 (04) 281-98.
• 33 Yeaman MR, Sullam PM, Dazin PF. et al. Platelet microbicidal protein alone and in combination with antibiotics reduces Staphylococcus aureus adherence to platelets in vitro. Infect Immun 1994; 62 (08) 3416-23.
• 34 Dhawan VK, Yeaman MR, Bayer AS. Influence of in vitro susceptibility phenotype against thrombin-induced platelet microbicidal protein on treatment and prophylaxis outcomes of experimental Staphylococcus aureus endocarditis. J Infect Dis 1999; 180 (05) 1561-8.
• 35 Mercier RC, Rybak MJ, Bayer AS. et al. Influence of platelets and platelet microbicidal protein susceptibility on the fate of Staphylococcus aureus in an in vitro model of infective endocarditis. Infect Immun 2000; 68 (08) 4699-705.